Atrial fibrillation.

[1]  L. Lund,et al.  Prognostic Significance of Resting Heart Rate and Use of &bgr;-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry , 2015, Circulation. Heart failure.

[2]  V. Hasselblad,et al.  Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. , 2015, The New England journal of medicine.

[3]  Saibal Kar,et al.  Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[4]  Christopher X. Wong,et al.  Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). , 2015, Journal of the American College of Cardiology.

[5]  S. Hohnloser,et al.  Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation , 2015, European heart journal.

[6]  Prashanthan Sanders,et al.  Approaches to catheter ablation for persistent atrial fibrillation. , 2015, The New England journal of medicine.

[7]  N. Geller,et al.  Surgical ablation of atrial fibrillation during mitral-valve surgery. , 2015, The New England journal of medicine.

[8]  T. Chao,et al.  Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? , 2015, Journal of the American College of Cardiology.

[9]  L. Friberg,et al.  Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. , 2015, Journal of the American College of Cardiology.

[10]  Y. Béjot,et al.  Hospitalization Within the First Year After Stroke: The Dijon Stroke Registry , 2015, Stroke.

[11]  G. Breithardt,et al.  Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial , 2014, European heart journal.

[12]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[13]  R. Mahajan,et al.  Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. , 2014, Journal of the American College of Cardiology.

[14]  E. Dolan,et al.  Acute Hospital, Community, and Indirect Costs of Stroke Associated With Atrial Fibrillation: Population-Based Study , 2014, Stroke.

[15]  Saibal Kar,et al.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.

[16]  S. Kalantarian,et al.  Association Between Atrial Fibrillation and Silent Cerebral Infarctions , 2014, Annals of Internal Medicine.

[17]  G. Fitzmaurice,et al.  Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control: Insights From a Prospective International Registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation RECORD-AF) , 2014, Circulation. Cardiovascular quality and outcomes.

[18]  J. Douketis,et al.  Approach to the new oral anticoagulants in family practice: part 1: comparing the options. , 2014, Canadian family physician Medecin de famille canadien.

[19]  J. Douketis,et al.  Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. , 2014, Canadian family physician Medecin de famille canadien.

[20]  Byron K. Lee,et al.  Atrial fibrillation: antiarrhythmic therapy. , 2014, Current problems in cardiology.

[21]  Klaus Gröschel,et al.  Finding atrial fibrillation in stroke patients: Randomized evaluation of enhanced and prolonged Holter monitoring--Find-AF(RANDOMISED) --rationale and design. , 2014, American heart journal.

[22]  Hung-Yi Chen,et al.  Long-term effect of antihypertensive drugs on the risk of new-onset atrial fibrillation: a longitudinal cohort study , 2014, Hypertension Research.

[23]  M. Kaps,et al.  Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice , 2014, BMC Neurology.

[24]  R. Damiano,et al.  A minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major morbidity and hospital stay. , 2014, The Journal of thoracic and cardiovascular surgery.

[25]  S. Parikh,et al.  Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. , 2014, Cardiovascular diagnosis and therapy.

[26]  J. Hartikainen,et al.  Time to cardioversion for acute atrial fibrillation and thromboembolic complications. , 2014, JAMA.

[27]  L. Chen,et al.  Physical Activity, Obesity, Weight Change, and Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study , 2014, Circulation. Arrhythmia and electrophysiology.

[28]  S. Larsson,et al.  Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. , 2014, Journal of the American College of Cardiology.

[29]  Frank Beckers,et al.  Cryptogenic stroke and underlying atrial fibrillation. , 2014, The New England journal of medicine.

[30]  David J Gladstone,et al.  Atrial fibrillation in patients with cryptogenic stroke. , 2014, The New England journal of medicine.

[31]  Stanley Nattel,et al.  Early management of atrial fibrillation to prevent cardiovascular complications. , 2014, European heart journal.

[32]  A. Capucci,et al.  Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events , 2014, Circulation.

[33]  B. Nordestgaard,et al.  Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. , 2014, European heart journal.

[34]  Stanley Nattel,et al.  The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. , 2014, Circulation research.

[35]  P. Ellinor,et al.  Emerging Directions in the Genetics of Atrial Fibrillation , 2014, Circulation research.

[36]  J. Reiffel.  Atrial fibrillation and stroke: epidemiology. , 2014, The American journal of medicine.

[37]  G. Lip,et al.  Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. , 2014, International journal of cardiology.

[38]  N. Lakkis,et al.  Oral anticoagulation in atrial fibrillation. , 2014, Cardiovascular & hematological agents in medicinal chemistry.

[39]  D. Singer,et al.  Long-term survival after ischemic stroke in patients with atrial fibrillation , 2014, Neurology.

[40]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[41]  A. Tveit,et al.  Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. , 2014, European heart journal.

[42]  K. Kario,et al.  Heavy alcohol consumption and risk of atrial fibrillation. The Circulatory Risk in Communities Study (CIRCS). , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[43]  J. Healey,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. , 2014, JAMA.

[44]  Zaid Alirhayim,et al.  Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. , 2014, The American journal of cardiology.

[45]  Shao-wen Liu,et al.  Atrial fibrillation in essential hypertension: an issue of concern , 2014, Journal of cardiovascular medicine.

[46]  Jamil Mayet,et al.  A Randomized Controlled Trial of Catheter Ablation Versus Medical Treatment of Atrial Fibrillation in Heart Failure (The CAMTAF Trial) , 2014, Circulation. Arrhythmia and electrophysiology.

[47]  L. Køber,et al.  Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant: A Nationwide Cohort Study , 2014, Circulation.

[48]  Kennedy R. Lees,et al.  Detection of Atrial Fibrillation After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis , 2014, Stroke.

[49]  B. Wessler,et al.  Controversies in Cardioembolic Stroke , 2014, Current Treatment Options in Cardiovascular Medicine.

[50]  M. Lai,et al.  Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. , 2014, Atherosclerosis.

[51]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[52]  H. Crijns,et al.  Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post‐hoc analysis of the RACE II study , 2013, European journal of heart failure.

[53]  M. O'Neill,et al.  Catheter ablation of atrial fibrillation in heart failure. , 2013, Heart failure clinics.

[54]  S. Connolly,et al.  Dabigatran versus warfarin in patients with mechanical heart valves. , 2013, The New England journal of medicine.

[55]  Hong-yan Lu,et al.  CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis , 2013, Journal of geriatric cardiology : JGC.

[56]  Y. Hao,et al.  Documentation of impaired coronary blood flow by TIMI frame count method in patients with atrial fibrillation. , 2013, International journal of cardiology.

[57]  T. Glotzer,et al.  Silent atrial fibrillation as a stroke risk factor and anticoagulation indication. , 2013, The Canadian journal of cardiology.

[58]  L. Køber,et al.  Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. , 2013, International journal of cardiology.

[59]  J. Cleland,et al.  Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. , 2013, European heart journal.

[60]  Tom Wong,et al.  A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. , 2013, Journal of the American College of Cardiology.

[61]  Anne B Curtis,et al.  Biventricular pacing for atrioventricular block and systolic dysfunction. , 2013, The New England journal of medicine.

[62]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[63]  P. Wenaweser,et al.  Atrial Fibrillation and Aortic Stenosis: Impact on Clinical Outcomes Among Patients Undergoing Transcatheter Aortic Valve Implantation , 2013, Circulation. Cardiovascular interventions.

[64]  C. Morillo,et al.  Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. , 2013, JAMA internal medicine.

[65]  D. Mukherjee,et al.  Pharmacologic Rate versus Rhythm‐Control Strategies in Atrial Fibrillation: An Updated Comprehensive Review and Meta‐Analysis , 2013, Pacing and clinical electrophysiology : PACE.

[66]  A. Glanz,et al.  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. , 2013, The New England journal of medicine.

[67]  S. Yusuf,et al.  Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease , 2012, Canadian Medical Association Journal.

[68]  L. Ling,et al.  Irregular Rhythm Adversely Influences Calcium Handling in Ventricular Myocardium: Implications for the Interaction Between Heart Failure and Atrial Fibrillation , 2012, Circulation. Heart failure.

[69]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[70]  W. Ageno,et al.  Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. , 2012, Archives of internal medicine.

[71]  G. Richards.  An overview of atrial fibrillation. , 2012, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[72]  G. Hindricks,et al.  ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[73]  Mårten Rosenqvist,et al.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.

[74]  G. Lip,et al.  Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study , 2012, Circulation.

[75]  J. Olesen,et al.  The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study , 2012, Thrombosis and Haemostasis.

[76]  Jagmeet P. Singh,et al.  Atrioventricular Nodal Ablation in Atrial Fibrillation: A Meta-Analysis and Systematic Review , 2012, Circulation. Arrhythmia and electrophysiology.

[77]  A. Capucci,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[78]  José Jalife,et al.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation , 2012, Heart rhythm.

[79]  M. Brignole,et al.  Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. , 2011, European heart journal.

[80]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[81]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[82]  Christopher E Hilker,et al.  Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. , 2011, Heart rhythm.

[83]  Niels Voigt,et al.  Recent advances in the molecular pathophysiology of atrial fibrillation. , 2011, The Journal of clinical investigation.

[84]  David O. Martin,et al.  Natural History and Long-Term Outcomes of Ablated Atrial Fibrillation , 2011, Circulation. Arrhythmia and electrophysiology.

[85]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[86]  A. Curtis,et al.  Relation of obesity to recurrence rate and burden of atrial fibrillation. , 2011, The American journal of cardiology.

[87]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[88]  S. Nattel.  From guidelines to bench: implications of unresolved clinical issues for basic investigations of atrial fibrillation mechanisms. , 2011, The Canadian journal of cardiology.

[89]  Michael J Pencina,et al.  Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. , 2010, JAMA.

[90]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[91]  Otto Kamp,et al.  Lenient versus strict rate control in patients with atrial fibrillation. , 2010, The New England journal of medicine.

[92]  Robby Nieuwlaat,et al.  Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. , 2010, Journal of the American College of Cardiology.

[93]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[94]  Elia Biganzoli,et al.  Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.

[95]  L. Køber,et al.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data , 2009, The Lancet.

[96]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[97]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[98]  S. Schneider,et al.  Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[99]  Dongfeng Qi,et al.  The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study , 2009, Circulation. Arrhythmia and electrophysiology.

[100]  S. Connolly,et al.  Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter , 2009, Circulation.

[101]  Matthew R. Reynolds,et al.  Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or Radiofrequency Ablation: Two Systematic Literature Reviews and Meta-Analyses , 2009, Circulation. Arrhythmia and electrophysiology.

[102]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[103]  Christopher X. Wong,et al.  Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the "second factor". , 2009, Journal of the American College of Cardiology.

[104]  K. Wachtell.  Atrial fibrillation, maybe it is not so lone? , 2009, Journal of the American College of Cardiology.

[105]  David O. Martin,et al.  Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. , 2008, The New England journal of medicine.

[106]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[107]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[108]  Shien-Fong Lin,et al.  Mechanisms of Atrial Fibrillation , 2003, Journal of cardiovascular electrophysiology.

[109]  T. Lumley,et al.  Risk of new-onset atrial fibrillation in relation to body mass index. , 2006, Archives of internal medicine.

[110]  S. Connolly,et al.  Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. , 2006, American heart journal.

[111]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[112]  E. Daoud,et al.  Left Ventricular‐Based Cardiac Stimulation Post AV Nodal Ablation Evaluation (The PAVE Study) , 2005, Journal of cardiovascular electrophysiology.

[113]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[114]  I. V. Van Gelder,et al.  Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. , 2005, American heart journal.

[115]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[116]  E. Kaufman,et al.  Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study , 2005 .

[117]  D. Reda,et al.  Amiodarone versus sotalol for atrial fibrillation. , 2005, The New England journal of medicine.

[118]  J. Wardlaw,et al.  What causes lacunar stroke? , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[119]  H. Crijns,et al.  Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. , 2005, Heart rhythm.

[120]  Prashanthan Sanders,et al.  Catheter ablation for atrial fibrillation in congestive heart failure. , 2004, The New England journal of medicine.

[121]  Paul Dorian,et al.  The association of left atrial size and occurrence of atrial fibrillation: A prospective cohort study from the Canadian Registry of Atrial Fibrillation , 2004 .

[122]  Brian Olshansky,et al.  The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[123]  M. Domanski,et al.  Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study , 2004, Circulation.

[124]  Otto Kamp,et al.  Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. , 2004, Journal of the American College of Cardiology.

[125]  Yuchiao Chang,et al.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.

[126]  J. Murabito,et al.  Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.

[127]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[128]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[129]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[130]  D. Grobbee,et al.  Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial , 2002, The Lancet.

[131]  C. Schmitt,et al.  Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. , 2001, European heart journal.

[132]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[133]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[134]  J B Seward,et al.  Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. , 2001, Mayo Clinic proceedings.

[135]  R. E. Donnelly,et al.  Management of new-onset atrial fibrillation. , 2001, JAAPA : official journal of the American Academy of Physician Assistants.

[136]  B. Gersh,et al.  Long-Term Survival after Ablation of the Atrioventricular Node and Implantation of a Permanent Pacemaker in Patients with Atrial Fibrillation , 2001 .

[137]  G. Kay,et al.  Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. , 2000, Mayo Clinic proceedings.

[138]  A. Mattioli,et al.  Serial evaluation of left atrial dimension after cardioversion for atrial fibrillation and relation to atrial function. , 2000, The American journal of cardiology.

[139]  S. Connolly,et al.  Amiodarone to Prevent Recurrence of Atrial Fibrillation , 2000 .

[140]  R. Steeds,et al.  An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation , 1999, Heart.

[141]  F. Morady,et al.  Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. , 1999, The New England journal of medicine.

[142]  S. Lévy,et al.  Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. , 1999, Circulation.

[143]  P A Wolf,et al.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.

[144]  F. Morady,et al.  Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery , 1997 .

[145]  G. Kay,et al.  Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. , 1997, Journal of the American College of Cardiology.

[146]  G. Lip,et al.  Original Papers , 2016 .

[147]  S. Ravid,et al.  The effect of atrial fibrillation and the ventricular rate control on exercise capacity , 1997, Clinical cardiology.

[148]  S. Connolly,et al.  Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. , 1996, European heart journal.

[149]  J. Soler‐Soler,et al.  Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. , 1996, Journal of the American College of Cardiology.

[150]  B. Maron,et al.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. , 1995, Journal of the American College of Cardiology.

[151]  H. Crijns,et al.  Left ventricular beat-to-beat performance in atrial fibrillation: contribution of Frank-Starling mechanism after short rather than long RR intervals. , 1995, Journal of the American College of Cardiology.

[152]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[153]  P. Whelton.  Epidemiology of hypertension , 1994, The Lancet.

[154]  S. Sharma.  Holiday heart syndrome. , 1994, The Journal of the Association of Physicians of India.

[155]  R. Page,et al.  Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. , 1994, Circulation.

[156]  M. Kamalesh,et al.  Management of atrial fibrillation. , 1992, The New England journal of medicine.

[157]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[158]  P Smith,et al.  The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.

[159]  M. Frenneaux,et al.  Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. , 1990, Journal of the American College of Cardiology.

[160]  J. Rawles,et al.  What is meant by a "controlled" ventricular rate in atrial fibrillation? , 1990, British heart journal.

[161]  T. Savides,et al.  Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. , 1989, The American journal of cardiology.

[162]  W. Kannel,et al.  Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.

[163]  P B Halmos,et al.  Effect of atrial fibrillation on cardiac output. , 1965, British heart journal.